Reviva Pharmaceuticals: Promising Schizophrenia Treatment Drives Buy Rating

Reviva Pharmaceuticals Holdings (RVPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Bruce Jackson from Benchmark Co. maintained a Buy rating on the stock and has a $14.00 price target.

Bruce Jackson has given his Buy rating due to a combination of factors related to Reviva Pharmaceuticals Holdings’ promising developments in their schizophrenia treatment. The company has shown positive long-term data from their open-label extension study, which is crucial for meeting FDA requirements and demonstrates the drug’s efficacy and tolerability. This data indicates that Brilaroxazine, their leading drug candidate, offers better efficacy, fewer side effects, and higher patient compliance compared to existing treatments, making it a strong candidate for partnerships.
Furthermore, the upcoming catalysts such as the release of the full dataset from the OLE trial, initiation of the RECOVER-2 Trial, and the NDA submission for Brilaroxazine are expected to drive the stock’s performance. Despite the need for additional capital to advance their clinical programs, the company’s strategic options, including partnerships and licensing, present opportunities for growth. These factors collectively support the Buy rating, reflecting confidence in the company’s potential to achieve significant milestones in the treatment of schizophrenia.

In another report released on April 4, Roth MKM also maintained a Buy rating on the stock with a $7.00 price target.